Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
axitinib + TRC105
- Development stage
- Unknown
- Lead developer
- TRACON Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Axitinib + TRC105 is an investigational combination therapy for metastatic renal cell carcinoma (mRCC). Axitinib is a small molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR) and inhibits angiogenesis. TRC105 (carotuximab) is a chimeric IgG1 monoclonal antibody against endoglin (CD105), a receptor highly expressed on proliferating endothelial cells and certain cancer stem cells, implicated in angiogenesis and resistance to VEGF inhibitors. The strategy of combining these two drugs aims to overcome resistance to VEGF-targeted therapies by dual inhibition of VEGF and endoglin pathways. While phase 1 studies showed the combination is tolerable and demonstrated preliminary antitumor activity in previously treated mRCC patients, a phase 2 study did not show benefit over axitinib monotherapy in advanced clear cell renal cell carcinoma[1][2][4][5].
- Brand names
- Inlyta
- Other names
- axitinib + carotuximab
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)ENG (Integrin Beta 6)
Beyond the preview
Go deeper on axitinib + TRC105.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on axitinib + TRC105.